News

PHEXCOM

Solution BY Communication

Call：+86 021-55807300

Position：Home > News >

Humanigen, Thermo Fisher strike deal to scale up manufacturing of monoclonal antibody for COVID-19

In the earliest days of the COVID-19 pandemic, a suite of drugmakers looked to monoclonal antibodies to fight the immune system overreaction seen in severe patients. Months later, most of those candi
2020/9/23
Sun Pharma the latest to recall metformin after carcinogen tests come up positive

Once cleared by the FDA of a probable carcinogen, generic diabetes med metformin has now been the target of a growingnumber of recalls. This week, a seventh drugmaker has joined the metformin recall
2020/9/23
Fujifilm's flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan

Six months after the World Health Organization declared COVID-19 a global pandemic, the list of drugs with proven efficacy againstthe virus remains short. On Wednesday, Fujifilm added itsflu drug Avi
2020/9/22
ICER rubber-stamps Vertex's $311K CF drug Trikafta but blasts 'monopoly' pricing

No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at the Institute for Clinical and Economic Review (ICER). But IC
2020/9/22
With U.S. elections nearing, European pharma giants brace for potential pricing action: analysts

With U.S. presidential and congressional campaignsin full swing, it’s not just Americans anxiously awaitingthe results of the upcoming elections. The races couldaffect European pharma companies in a
2020/9/21
Pfizer leans into gene therapy manufacturing with 'build-buy-partner' strategy

In the bustling cell and gene therapy field, manufacturing is a major hurdle for drugmakers hoping to bring 10 to 20 new products to market each year in the coming decade. Pfizer has invested big mon
2020/9/21
BioNTech, CureVac bag $745M in German funding for COVID-19 vaccine hopefuls

Two German biotechs, BioNTech and CureVac, have been at the cutting edge of the hunt for a COVID-19 vaccine—a time-consuming and costly process. In order to get both over the finish line, the German
2020/9/17
Gilead needs 'heroic' Immunomedics revenues to get a return on $21B deal: analyst

Gilead Sciences has long needed to diversify beyond its core antivirals business, and oncology seemeda wise choice for expansion. But should it be paying $21 billion for Immunomedics? Analysts have s
2020/9/16
Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy is Takeda's next-gen cell
2020/9/16
Novavax adds antigens to COVID-19 production pact with Indian vaccines giant

Despite a lackluster history of taking vaccines to market, Maryland's Novavax is streaking through clinical trials for its promising COVID-19 shot candidate. Going commercial is a whole other beast,
2020/9/15

Excipients